Activity Overview
This educational activity is an archive of the live presentation held on February 17, 2026.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward hematologist-oncologists, pathologists, advanced practice providers, pharmacists, nurses, and other health care providers involved in the management of patients with AML.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Determine the mechanistic rationale supporting the role of menin inhibitors in AML treatment
- Discuss the potential implications of recent trial evidence and emerging monotherapy/combination therapy trials evaluating menin inhibitors in patients with AML
- Develop individualized care plans for patients with NPM1m and/or KMT2A-r AML based on clinical trial evidence
- Devise strategies to proactively monitor and mitigate treatment-related toxicities and/or treatment resistance in patients with AML receiving menin inhibitors
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login HereAccreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.
Physicians’ Education Resource®, LLC (PER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Physicians’ Education Resource®, LLC has approved this application-based activity for 1.50 ACPE CE hours UAN # 0661-0000-26-001-H01-P. Eligibility for credits requires full attendance, engagement in the live activity, completion and submission of the learner NABP ID # and month and day of birth, activity pre/post-session questions, and the post activity evaluation.
Acknowledgment of Commercial Support
This activity is supported by educational grants from Janssen Scientific Affairs, LLC; Kura Oncology; and Syndax Pharmaceuticals.